StreetAlpha.app
Home › Stocks › TRAW

Traws Pharma, Inc. (TRAW)

$0.23
▼ −10.27%
LAST CLOSE · NOV 17

Traws Pharma develops investigational antiviral medicines for respiratory viral diseases such as influenza and COVID-19. It last closed at $0.23 on Nov 17, down 10.27% on the day.

AI Auto Pilots
Is TRAW in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$22.3M
EPS (diluted)
−$1.57
Valuation
Market cap
$3.6M
15.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$2.3M
At Sep 30
Shares outstanding
15.4M
At Nov 12
Employees17 (Apr 8, 2024)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $226K$226KFY2021FY2022: $226K$226KFY2022FY2023: $226K$226KFY2023FY2024: $226K$226KFY2024FY2025: $2.8M$2.8MFY2025

From TRAW's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated TRAW in the past 90 days.
Average 12-month target
No price targets on TRAW in the past 90 days.
Latest rating changes
HC Wainwright & Co.Reiterated
Aug 18Hold$1
HC Wainwright & Co.Downgrade
Jun 18Hold$8 → $1
HC Wainwright & Co.Reiterated
May 20Buy$8
DateFirmActionRatingPrice target
Aug 18HC Wainwright & Co.ReiteratedHold$1
Jun 18HC Wainwright & Co.DowngradeHold$8 → $1
May 20HC Wainwright & Co.ReiteratedBuy$8
Loading…

Technical Analysis

TRAW · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 25% below its 20 day and 78% below its 50 day average. It is 347% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 33), near oversold. The nearest support is the 52 week low at $0.22, and the nearest resistance the Pivot at $0.25.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 16.4%/day
Key levels
$3.2352 week high+1304.3%
$1.04200 day average+352.2%
$0.51100 day average+121.7%
$0.4250 day average+82.6%
$0.30Swing high (Nov 12)+30.4%
$0.2920 day average+26.1%
$0.26Pivot R1+13.0%
$0.25Pivot+8.7%
$0.23Last close
$0.2252 week low−4.3%
$0.22Pivot S1−4.3%
$0.22Swing low (Nov 5)−4.3%
Indicators
RSI (14)33.27Weak, oversold below 30Neutral
MACD-0.05Below its signal lineBearish
Stochastic19.4Near the bottom of its rangeOversold
ADX (14)28.0Trending down
Williams %R-90.3Oversold below −80, overbought above −20Oversold
CCI (20)-71.8Oversold below −100, overbought above 100Neutral
Rate of change−22.8%Change over 10 sessionsBearish
ATR (14)$0.04Typical daily range, 16.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TRAW

What happened before

See how TRAW did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TRAW usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TRAW has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in TRAW in the last 90 days.

Loading…

See today’s whale options flow across the market →

TRAW Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼9 buying vs 11 selling
  • ▼Held by funds -1.7 pts
  • ▼Funds holding -1
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3334−2.9%
In funds' top 1000–
Held by funds38.4%40.1%−1.7 pts
New / increased5 / 413 / 9−59.1%
Reduced / sold out6 / 58 / 7−26.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TRAW institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TRAW is in one of them and how their past TRAW trades turned out.

TRAW in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TRAW in an article yet. Here's the latest on the wider market.

About Traws Pharma

Traws Pharma is a clinical stage biopharmaceutical company based in Newtown, Pennsylvania. It is developing investigational antiviral medicines for respiratory viral diseases, including influenza, bird flu and COVID-19. Its main candidate, tivoxavir marboxil, is being studied as a single dose oral treatment and as a monthly oral option to prevent influenza. The company also has cancer programs in clinical development. Its candidates are aimed at patients, and none is yet approved for sale.

Headquarters
Newtown, PA